Objective:

The article lists clinical trials in age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and uveitis.

Approach:

• Coverage: The listing is organized by retinal disease area and includes study purpose, design, planned enrollment, sponsor, and contact information where provided.
• Dry AMD and GA: The excerpt describes studies of investigational drugs, gene-based approaches, dietary intervention, imaging, and anesthesia for intravitreal injections.

Key Findings:

• The excerpt lists a Phase 3 OCU410 study for GA secondary to dry AMD, with planned enrollment of 237 participants.
• Other GA studies include Phase 2 trials of oral STL303 (300 participants) and FWY003 (272 participants), and a Phase 1/2 study of subretinal CTx001 (75 participants).
• Additional listed investigations include a 10-participant imaging pilot, a 32-participant dietary intervention feasibility study, and a 236-participant Phase 4 anesthesia comparison.
• The listing identifies two studies as terminated: RO7669330 in GA and REGN7041 for active noninfectious uveitis.

Interpretation:

The supplied excerpt is a trial listing that describes study aims and designs; it does not report efficacy or safety results.

Limitations:

• The context ends mid-entry at “A Safety and Eff,” so the remainder of the listing is unavailable.
• Although the introduction names AMD, DME, RVO, and uveitis, the supplied trial details are largely limited to dry AMD and GA.
• The source URL for the article itself was not provided.

Conclusion:

The excerpt lists trials across retinal disease areas, with the supplied study details focused largely on dry AMD and geographic atrophy.

Sources:

• ClinicalTrials.gov: RO7669330 (NCT06961370)
• ClinicalTrials.gov: REGN7041 / TITAN (NCT07218770)
• ClinicalTrials.gov: OCU410 (NCT07770828)
• ClinicalTrials.gov: Adaptive optics and microperimetry substudy (NCT07747662)
• ClinicalTrials.gov: GLOVE (NCT07605468)
• ClinicalTrials.gov: STL303 (NCT07606365)
• ClinicalTrials.gov: FWY003 (NCT07441642)
• ClinicalTrials.gov: QUELL (NCT07456826)
• ClinicalTrials.gov: ABF-101 (NCT07330674)
• ClinicalTrials.gov: Opti-GAIN / CTx001 (NCT07392255)
• ClinicalTrials.gov: BS01 (NCT07158775)
• ClinicalTrials.gov: SGLT2 inhibitors in GA (NCT07174687)
• ClinicalTrials.gov: Pozelimab / VIENNA (NCT07230834)
• ClinicalTrials.gov: ONL1204 (NCT06659445)